5-Bromo-3-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-2-methyl-3,4-dihydropyrimidin-4-one

Catalog No. :
ACRRYM087
CAS No. :
1537304-89-4
Molecular Formula :
C10H11BrN4O2
Molecular Weight :
299.13

IUPAC Name:5-bromo-3-((3-ethyl-1,2,4-oxadiazol-5-yl)methyl)-2-methylpyrimidin-4(3H)-one

5-Bromo-3-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-2-methyl-3,4-dihydropyrimidin-4-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$310.00Login to see priceInquiryInquiry
100mg95%$455.00Login to see priceInquiryInquiry
250mg95%$643.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Bromo-3-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-2-methyl-3,4-dihydropyrimidin-4-one
IUPAC Name5-bromo-3-((3-ethyl-1,2,4-oxadiazol-5-yl)methyl)-2-methylpyrimidin-4(3H)-one
MDL No.MFCD22315091
Molecular FormulaC10H11BrN4O2
Molecular Weight299.13
SMILESO=C1N(CC2=NC(CC)=NO2)C(C)=NC=C1Br
InChI KeyBJXKHWNYZUUFFI-UHFFFAOYSA-N
Synonym5-bromo-3-((3-ethyl-1,2,4-oxadiazol-5-yl)methyl)-2-methylpyrimidin-4(3H)-one;5-Bromo-3-[(3-Ethyl-1,2,4-Oxadiazol-5-Yl)Methyl]-2-Methyl-3,4-Dihydropyrimidin-4-One;4(3H)-Pyrimidinone, 5-bromo-3-[(3-ethyl-1,2,4-oxadiazol-5-yl)methyl]-2-methyl-
CAS No.1537304-89-4

Synthetic Route by SureRoute

1. ACRRYM087 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACGBNH342 route compound structure diagram
    ACGBNH3421676-57-9 In Stock
  4. Then
  5. ACRRYM087 route product structure diagram
    ACRRYM0871537304-89-4
Inquiry

2. ACRRYM087 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACGBNH342 route compound structure diagram
    ACGBNH3421676-57-9 In Stock
  4. Then
  5. ACRRYM087 route product structure diagram
    ACRRYM0871537304-89-4
Inquiry

Comments (0)